NCT02681861View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Healthy SubjectsPharmacokinetics of ASP6294

Interventions

DRUG

ASP6294 Intravenous

Intravenous (IV)

DRUG

ASP6294 Subcutaneous

Subcutaneous (SC)

DRUG

Placebo Intravenous

Intravenous (IV)

DRUG

Placebo Subcutaneous

Subcutaneous (SC)

Trial Locations (1)

HA1 3UJ

Site GB44001, Harrow

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02681861 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects | Biotech Hunter | Biotech Hunter